{
    "clinical_study": {
        "@rank": "53601", 
        "arm_group": [
            {
                "arm_group_label": "FDC empagliflozin dose 1 and metformin", 
                "arm_group_type": "Experimental", 
                "description": "fix dose combination tablet after intake of a high fat, high caloric meal"
            }, 
            {
                "arm_group_label": "empagliflozin dose 1 + metformin tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "single tablets after intake of a high fat, high caloric meal"
            }, 
            {
                "arm_group_label": "FDC empagliflozin dose 2 and metformin", 
                "arm_group_type": "Experimental", 
                "description": "fix dose combination tablet after intake of a high fat, high caloric meal"
            }, 
            {
                "arm_group_label": "empagliflozin dose 2 + metformin tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "single tablets after intake of a high fat, high caloric meal"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to establish bioequivalence of two fixed dose\n      combination (FDC) tablets (containing medium dose empagliflozin/500 mg metformin [Test 1]\n      and low dose empagliflozin/500 mg metformin [Test 2]) and of the single tablets (medium dose\n      empagliflozin tablets + Glucophage\u00ae 500 mg tablet [Reference 1] and low dose empagliflozin\n      tablet + Glucophage\u00ae 500 mg tablet [Reference 2]) when administered together after a high\n      fat, high caloric meal.\n\n      The assessment of safety and tolerability will be an additional objective of this trial."
        }, 
        "brief_title": "Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy male and female subjects\n\n          2. Subjects must be able to understand and comply with study requirements\n\n          3. Age 18 to 50 years\n\n          4. Body mass index (BMI) 18.5 to 29.9 kg/m2\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844531", 
            "org_study_id": "1276.6", 
            "secondary_id": "2012-000082-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "empagliflozin dose 1 + metformin tablets", 
                "description": "single tablet empagliflozin", 
                "intervention_name": "empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "empagliflozin dose 1 + metformin tablets", 
                "description": "single tablet metformin", 
                "intervention_name": "metformin (Glucophage\u00ae)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "empagliflozin dose 2 + metformin tablets", 
                "description": "single tablet metformin", 
                "intervention_name": "metformin (Glucophage\u00ae)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "empagliflozin dose 2 + metformin tablets", 
                "description": "single tablet empagliflozin", 
                "intervention_name": "empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FDC empagliflozin dose 1 and metformin", 
                "description": "FDC tablet empagliflozin and metformin", 
                "intervention_name": "empagliflozin and metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FDC empagliflozin dose 2 and metformin", 
                "description": "FDC tablet empagliflozin and metformin", 
                "intervention_name": "empagliflozin and metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1276.6.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Bioequivalence of Empagliflozin/Metformin (500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after drug intake"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after drug intake"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844531"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
            "safety_issue": "No", 
            "time_frame": "up to 72 hours after drug intake"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}